Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2002 December;93(6) > Minerva Medica 2002 December;93(6):479-84

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,878


eTOC

 

ORIGINAL ARTICLES  


Minerva Medica 2002 December;93(6):479-84

Copyright © 2002 EDIZIONI MINERVA MEDICA

language: English

Immunocytochemical profile of malignant pleural effusions of small-cell lung cancer

Tamiolakis D., Papadopoulos N., Cheva A., Lambropoulou M., Kotini A., Mikroulis D., Didilis V., Bitzikas N., Bougioukas G.


PDF  


Background. Small-cell lung carcinoma (SCLC) is a highly malignant tumour of a somewhat distinctive cell type. The aim of this study was to determine the immunocytochemical profile of tumor cells and lymphoid cell in SCLC pleural fluids.
Methods. Nine cases of malignant pleural fluids of SCLC were studied using cell block preparation. In pleural effusions cytologically proven to be malignant in 9 patients with SCLC, the immunocytological features of tumor cells, together with the determination of lymphocytic subsets were documented.
Results. In all 9 cases, tumor cells reacted with neuron-specific enolase (NSE) (100%), whereas in 6 of 9 cases (66,66%) tumor cell expressed synaptophysin, thyroid transciption factor-1 (TTF-1) and chromogranin A antigens. Phenotyping of the lymphocytes revealed in the majority of cases an expression of CD3 and CD4 antigens (8 and 7 cases, respectively) in contrast to CD8 and CD20 expression (1 and 1 case, respectively).
Conclusions. The reactivity pattern of the tumor cells with the markers used in our study is a specific for SCLC. No significant difference in the distribution of lymphocytic subpopulations is observed in correlation with other malignant and no malignant processes involving the pleural cavity.

top of page

Publication History

Cite this article as

Corresponding author e-mail